Aileron Therapeutics, Inc. Stock

$0.77

3.07%

Nasdaq, Wed, Sep 23 2026.

ISIN

US00887A1051

Symbol

ALRN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Analysts Charts Ownership Strategies

Aileron Therapeutics, Inc. Stock price

$0.77

-20.83 96.43% 5Y

Nasdaq, Closing price Wed, Sep 23 2026

-0.02 3.07%

ISIN

US00887A1051

Symbol

ALRN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Get Started for Free Today

Key metrics

Basic

Market capitalization

$66.5m

Enterprise Value

$25.8m

Net debt

positive

Cash

$40.7m

Shares outstanding

85.8m

Valuation (TTM | estimate)

P/E

negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

1.2

Financial Health

Equity Ratio

70.0%

Return on Equity

-294.8%

ROCE

-87.9%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-49.5m

EBIT

$-49.5m

Net Income

$-49.8m

Free Cash Flow

$-18.8m

Growth (TTM | estimate)

Revenue

- | -

EBITDA

19.4%

EBIT

19.4%

Net Income

15.9%

Free Cash Flow

11.3%

Margin

Gross

EBITDA

EBIT

Net

Free Cash Flow

EPS

$-0.7

FCF per Share

$-0.2

Short interest

1.1%

Employees

Rev per Employee

$0.0

Aileron Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Aileron Therapeutics, Inc. forecast:

7x Buy

78%

2x Hold

22%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Aileron Therapeutics, Inc. forecast:

Buy

78%

Hold

22%

Analyst Estimates with Stock Price Targets

Aileron Therapeutics, Inc. Events

Past Events

JUL

Shareholder/Analyst Call - Rein Therapeutics Inc.

2 months ago

1. Management Discussion

Operator

Hello, and welcome to the 2026 Annual Meeting of Stockholders of Rein Therapeutics, Inc. Please note that today's meeting is being recorded. [Operator Instructions]

It is now my pleasure to turn today's meeting over to Brian Windsor, President and Chief Executive Officer of Rein Therapeutics Inc., Dr. Windsor, the floor is yours.

Brian Windsor executive

Good morning, and welcome to the 2026 Annual Meeting of Stockholders of Rein Therapeutics, Inc. I am Brian Windsor, President and Chief Executive Officer of Rein, and I will be presiding over this meeting.

At this time, I call the meeting to order. This year, we are holding our annual meeting in an all-virtual format and are pleased to have everyone join this live webcast. We have designed this meeting to provide stockholders the same rights and opportunities to participate as they would at an in-person meeting.

Before we get to the formal business of the meeting, I would like to make some introductions. Joining us at the meeting today are: Josef H. von Rickenbach, our Chairman and Director, Alan A. Musso. Also from our management team, Tim Cunningham, Interim Chief Financial Officer.

I would also like to introduce Sharona Ellevold, a representative from Computershare Trust Company N.A., our transfer agent, and she has been appointed to act as Inspector of Election.

In order to conduct an orderly meeting, I call your attention to the rules of nduct posted on the virtual meeting website, which include information about participating in the meeting, including asking questions.

I have received an affidavit from the company's transfer agent, Computershare Trust Company N.A., certifying that the notice of the annual meeting and proxy statement were sent to all stockholders of record as of May 21, 2026.

Our first order of business at this meeting is to determine whether the shares represented at this meeting, either in person via this virtual meeting or by proxy, are sufficient to constitute a quorum for the purpose of transacting business. Holders of 85,539,032 shares of common stock are entitled to vote at this meeting. The Inspector of Election has informed me that they are present at this meeting, either in person or by proxy a total of 63,703,884 shares of common stock or approximately 74.7% of all shares entitled to vote at this meeting. Therefore, I hereby declare that a quorum exists.

Turning now to the items to be voted on at this meeting, as indicated in the notice of meeting and accompanying documents that were made available to stockholders.

The first matter to be voted on is the election of 2 Class III directors to serve for a term expiring at the 2029 Annual Meeting of Stockholders and until his successor is duly elected and qualified.

The nominees for this election are Josef H. von Rickenbach and Reinhard J. Ambrose Ph.D. The second matter to be voted on is the approval of an increase in the authorized shares. The third matter to be voted on is the approval of CBIZ as the company's independent audit firm. The fourth and final matter to be voted on is the approval, on a nonbinding advisory basis, of our named executive officer compensation.

If there are any questions on the proposals, they may be submitted on the virtual meeting website. If asking a question, please also include your name and affiliation to the company.

Tim, do we have any questions germane to the meeting at this time?

Timothy Cunningham executive

Brian, there are no questions germane to the meeting.

Brian Windsor executive

Thank you. I hereby declare the polls are now open for each matter to be voted upon today. If you have not yet voted or if you have previously voted by proxy and wish to change your vote, you may vote by using the Cast Your Vote link provided on the virtual meeting website and following the instructions there. We will pause briefly to allow stockholders to vote.

[Voting]

Brian Windsor executive

Now that everyone has had an opportunity to vote, the business items on the agenda for this meeting are complete, and the polls are now closed.

Will Sharona Ellevold please tabulate the votes?

We now have the preliminary report of the results of the meeting. Based on this report, the nominees for directors have been elected as Class III directors; the increase in the number of authorized shares has been approved; CBIZ has been appointed as the company's independent audit firm; the compensation of named executive officers on a nonbinding advisory basis has been approved.

The final vote results will be included in the Form 8-K that will be filed within 4 business days after this meeting.

As there is no further business to come before the meeting, I would like to thank each stockholder who sent in a proxy for this meeting, and I especially would like to thank you who are here for virtually attending.

I hereby declare this meeting adjourned.

Operator

The meeting has now concluded. Thank you for joining. You may now disconnect.

Financial data from Aileron Therapeutics, Inc.

Income StatementP&L Balance Sheet Cash Flow

Quarter TTM Annually

Jun '26		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	10 10	4% 4% -
- Research and Development Expense	10 10	28% 28% -
EBITDA	-49 -49	19% 19% -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-49 -49	19% 19% -
Net Profit	-50 -50	16% 16% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Company Profile

Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.

Head office	United States
CEO	Dr. Windsor
Employees	10
Founded	2001
Website	www.reintx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now